David Leffell

Last updated

David J. Leffell, MD, was born in 1956 in Montreal, Canada and educated at McGill University and Yale University. He is founder and chief of the Dermatologic Surgery Program at Yale School of Medicine. Leffell is an internationally recognized expert in skin cancer and the Mohs technique, plastic reconstruction, and new technologies in dermatology. He specializes in the diagnosis, treatment, and prevention of melanoma and nonmelanoma skin cancer. [1] He is the David Paige Smith Professor of Dermatology and Surgery, [2] chief of Dermatologic Surgery and Cutaneous Oncology, [3] and former Deputy Dean for Clinical Affairs at Yale University School of Medicine . In January 2012, Dr. Leffell stepped down as chief executive officer of the Yale Medical Group , after 15 years of leadership of the organization. He serves on the board of Validus Pharmaceuticals and is a trustee of The Hopkins School, one of America's oldest independent schools.

Contents

Research

While still in medical training, Leffell developed and patented a laser method for measuring the aging of skin. [4] With Douglas Brash and others he has also published work that clarifies the genetic basis of the cancer-causing ultraviolet rays of the sun. [5] This work represented proof that an environmental agent could directly be linked to a genetic injury that causes cancer . Leffell was a member of the international team that discovered PTC1, a tumor suppressor gene that plays a critical role in the development of hereditary and sporadic basal cell cancer. [6] He shares patents for the PTC gene [7] and PTCH protein. [8] In 2012, GenentechRoche introduced an oral medication based on the related hedgehog pathway [9] Leffell also invented a simple office-based method for the treatment of vitiligo, a depigmenting disorder for which treatment is otherwise limited. [10] In collaboration with Susan Mayne, PhD at the Yale School of Public Health, Leffell has researched the role of tanning parlors in the development of skin cancer in young women. [11]

Publications

Dr. Leffell is the author or co-author of more than 130 publications, book chapters, and other media. He is an editor of the world's leading textbook of dermatology, Fitzpatrick’s Dermatology in General Medicine. He is also author of Manual of Skin Surgery (English and Chinese editions), a highly illustrated textbook of fundamental skin surgery for medical students, residents, and all specialties involved in skin surgery. A second English edition was published in 2012 Manual of Skin Surgery. Leffell also wrote Total Skin: The Definitive Guide to Whole Skin Care for Life, a "user-friendly" book intended to educate the general public about skin health. The book, originally published by Hyperion in 2000 has become a standard reference for the lay public on all aspects of skin health and disease and is now available as an ebook Totalskinandhealth. He has held editorial positions with many dermatology journals, including the Archives of Dermatology, The Journal of Dermatologic Surgery and Oncology, and Medical & Surgical Dermatology and is on the editorial board of Faculty of 1000. Leffell also appears extensively in print, on television, on the radio and on the web. In addition to medical publications, Leffell has appeared in The Enlightened Bracketologist with a chapter on Longevity and the Final Four of Everything writing on ways to enhance and preserve a youthful appearance. In 2011 Leffell published Connecticut Pastoral, a collection of photographs of the Connecticut Berkshires (Gaoh Press). In 2012, with colleagues Sumaira Aasi, MD of Stanford and Rossitza Lazova, MD of Yale, Leffell published Atlas of Practical Mohs Histopathology.

Yale Medical Group

Leffell has held successive leadership positions in the clinical practice at Yale since 1996. The group practice currently includes more than 900 full-time Yale School of Medicine faculty physicians who practice in more than 60 locations throughout the state of Connecticut. Leading a team of operations and strategic executives he focused on developing a patient-centered approach in a large, complex specialty organization. [12] In addition to overseeing a major branding initiative (converting the Yale faculty practice to the Yale Medical Group) and professionalizing the business operations of the organization, he spearheaded initiatives focused on enhanced patient service and integration of clinical research and clinical trials with the clinical practice. Leffell also oversaw the development of the medical billing compliance program and initiated the first program for faculty on the "Business of Medicine". Stephen Rimar, MD, who helped develop the program published one of the first textbooks of its kind based on the multidisciplinary lectures intended to provide practicing clinicians with fundamental knowledge of business. In 2010, with colleagues at Yale New Haven Hospital, he led the selection of Epic as the electronic medical record for Yale School of Medicine and the Yale New Haven Health System. Leffell reported on the effort in the CEO Newsletter of the Yale Medical Group. Leffell also believes that the cost/value paradox of academic medical centers is sustainable but requires thoughtful change. The centers, which represent huge capital investment, will always be the high cost providers of healthcare but will also be the source of cost-reducing innovation in medical care. The essay The Ostrich and the Wolf appeared in a communication to the faculty and staff of the Yale Medical Group.

Education

Dr. Leffell received his undergraduate degree in biology from Yale College where he was on the editorial board of the Yale Daily News and a resident of Pierson College. He returned to Montreal to attend McGill University Faculty of Medicine where he received his MD, CM degree in 1981. He completed residencies in internal medicine at Cornell Cooperating Hospitals and in dermatology at Yale New Haven Hospital. At Yale, he also completed a post-doctoral research year as a National Institutes of Health research fellow. Following his residencies, he completed a fellowship in advanced dermatologic surgery at the University of Michigan. Dr. Leffell founded the Dermatologic Surgery and Cutaneous Oncology program at Yale in 1988.

Related Research Articles

<span class="mw-page-title-main">Skin cancer</span> Medical condition involving uncontrolled growth of skin cells

Skin cancers are cancers that arise from the skin. They are due to the development of abnormal cells that have the ability to invade or spread to other parts of the body. Skin cancer is the most commonly diagnosed form of cancer in humans. There are three main types of skin cancers: basal-cell skin cancer (BCC), squamous-cell skin cancer (SCC) and melanoma. The first two, along with a number of less common skin cancers, are known as nonmelanoma skin cancer (NMSC). Basal-cell cancer grows slowly and can damage the tissue around it but is unlikely to spread to distant areas or result in death. It often appears as a painless raised area of skin that may be shiny with small blood vessels running over it or may present as a raised area with an ulcer. Squamous-cell skin cancer is more likely to spread. It usually presents as a hard lump with a scaly top but may also form an ulcer. Melanomas are the most aggressive. Signs include a mole that has changed in size, shape, color, has irregular edges, has more than one color, is itchy or bleeds.

Dermatology is the branch of medicine dealing with the skin. It is a speciality with both medical and surgical aspects. A dermatologist is a specialist medical doctor who manages diseases related to skin, hair, nails, and some cosmetic problems.

<span class="mw-page-title-main">Cutaneous squamous-cell carcinoma</span> Medical condition

Cutaneous squamous-cell carcinoma (cSCC), also known as squamous-cell carcinoma of the skin or squamous-cell skin cancer, is one of the three principal types of skin cancer, alongside basal-cell carcinoma and melanoma. cSCC typically presents as a hard lump with a scaly surface, though it may also present as an ulcer. Onset and development often occurs over several months. Compared to basal cell carcinoma, cSCC is more likely to spread to distant areas. When confined to the epidermis, the outermost layer of the skin, the pre-invasive or in situ form of cSCC is termed Bowen's disease.

<span class="mw-page-title-main">Basal-cell carcinoma</span> Most common type of skin cancer

Basal-cell carcinoma (BCC), also known as basal-cell cancer, basalioma or rodent ulcer, is the most common type of skin cancer. It often appears as a painless raised area of skin, which may be shiny with small blood vessels running over it. It may also present as a raised area with ulceration. Basal-cell cancer grows slowly and can damage the tissue around it, but it is unlikely to spread to distant areas or result in death.

<span class="mw-page-title-main">Benign tumor</span> Mass of cells which cannot spread throughout the body

A benign tumor is a mass of cells (tumor) that does not invade neighboring tissue or metastasize. Compared to malignant (cancerous) tumors, benign tumors generally have a slower growth rate. Benign tumors have relatively well differentiated cells. They are often surrounded by an outer surface or stay contained within the epithelium. Common examples of benign tumors include moles and uterine fibroids.

<span class="mw-page-title-main">Chandler Park</span> American physician

Chandler Park is an American physician, medical journalist, and clinical researcher. In June 2021, his cancer research was published in prominent medical journals including the New England Journal of Medicine and Journal of Clinical Oncology. Park also contributes regularly as an expert physician for popular newspapers and magazines such as Newsweek, Reader's Digest, U.S. News & World Report, The Exponent-Telegram, College of St. Scholastica, and Medscape and writes medical news for Doximity.

<span class="mw-page-title-main">Invasive carcinoma of no special type</span> Medical condition

Invasive carcinoma of no special type, invasive breast carcinoma of no special type (IBC-NST), invasive ductal carcinoma (IDC), infiltrating ductal carcinoma (IDC) or invasive ductal carcinoma, not otherwise specified (NOS) is a disease. For international audiences this article will use "invasive carcinoma NST" because it is the preferred term of the World Health Organization (WHO).

<span class="mw-page-title-main">Merkel-cell carcinoma</span> Rare and highly aggressive skin cancer

Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer occurring in about three people per million members of the population. It is also known as cutaneous APUDoma, primary neuroendocrine carcinoma of the skin, primary small cell carcinoma of the skin, and trabecular carcinoma of the skin. Factors involved in the development of MCC include the Merkel cell polyomavirus, a weakened immune system, and exposure to ultraviolet radiation. Merkel cell carcinoma usually arises on the head, neck, and extremities, as well as in the perianal region and on the eyelid. It is more common in people over sixty years old, Caucasian people, and males. MCC is less common in children.

<span class="mw-page-title-main">Mohs surgery</span> Surgery used to treat skin cancers

Mohs surgery, developed in 1938 by a general surgeon, Frederic E. Mohs, is microscopically controlled surgery used to treat both common and rare types of skin cancer. During the surgery, after each removal of tissue and while the patient waits, the tissue is examined for cancer cells. That examination dictates the decision for additional tissue removal. Mohs surgery is the gold standard method for obtaining complete margin control during removal of a skin cancer using frozen section histology. CCPDMA or Mohs surgery allows for the removal of a skin cancer with very narrow surgical margin and a high cure rate.

<span class="mw-page-title-main">Nevoid basal-cell carcinoma syndrome</span> Medical condition

Nevoid basal-cell carcinoma syndrome (NBCCS) is a rare inherited medical condition involving defects within multiple body systems such as the skin, nervous system, eyes, endocrine system, and bones. People with NBCCS are prone to developing various cancers, including a common and usually non-life-threatening form of non-melanoma skin cancer called basal-cell carcinomas (BCCs). Only about 10% of people with the condition do not develop BCCs; the vast majority of patients develop numerous BCCs.

<span class="mw-page-title-main">Vulvar cancer</span> Cancer involving the vulva

Vulvar cancer is a cancer of the vulva, the outer portion of the female genitals. It most commonly affects the labia majora. Less often, the labia minora, clitoris, or Bartholin's glands are affected. Symptoms include a lump, itchiness, changes in the skin, or bleeding from the vulva.

<span class="mw-page-title-main">Steven Libutti</span> American surgeon and scientist

Steven Kenneth Libutti, M.D., F.A.C.S. is an American surgeon and scientist. In January 2017, he became the third permanent Director of the Rutgers Cancer Institute of New Jersey, Vice Chancellor for Cancer Programs for Rutgers Biomedical and Health Sciences and the Senior Vice President for Oncology Services for RWJBarnabas Health, the largest health system in New Jersey. He is a tenured Distinguished Professor of Surgery at the Rutgers Robert Wood Johnson Medical School. Libutti's work on the study of tumor angiogenesis and the tumor microenvironment has led to novel approaches for the treatment of cancer. He is also one of the pioneers of regional and targeted cancer therapy.

<span class="mw-page-title-main">Atypical fibroxanthoma</span> Medical condition

Atypical fibroxanthoma (AFX) of the skin is a low-grade malignancy related to malignant fibrous histiocytoma, which it resembles histologically. Atypical fibroxanthoma manifests as a hard, pink or red papule or nodule that grows over the course of several months and may bleed or ulcerate. They typically occur on the head and neck. Atypical fibroxanthoma is usually asymptomatic.

<span class="mw-page-title-main">John E. Niederhuber</span>

John E. Niederhuber was the 13th director of the National Cancer Institute (NCI), from 2006 until July, 2010, succeeding Andrew von Eschenbach, who went on to become a director at biotechnology firm BioTime. A nationally renowned surgeon and researcher, Dr. Niederhuber has dedicated his four-decade career to the treatment and study of cancer - as a professor, cancer center director, National Cancer Advisory Board chair, external advisor to the NCI, grant reviewer, and laboratory investigator supported by NCI and the National Institutes of Health. He is now Executive Vice President/CEO Inova Translational Medicine Institute and Inova Health System and co-director, Johns Hopkins Clinical Research Network.

<span class="mw-page-title-main">Bernard Fisher (scientist)</span> American biologist

Bernard Fisher was an American surgeon and a pioneer in the biology and treatment of breast cancer. He was a native of Pittsburgh. He was Chairman of the National Surgical Adjuvant Breast Project at the University of Pittsburgh School of Medicine. His work established definitively that early-stage breast cancer could be more effectively treated by lumpectomy, in combination with radiation therapy, chemotherapy, and/or hormonal therapy, than by radical mastectomy.

<span class="mw-page-title-main">David Gorski</span> Science-based medicine advocate

David Henry Gorski is an American surgical oncologist and professor of surgery at Wayne State University School of Medicine. He specializes in breast cancer surgery at the Karmanos Cancer Institute. Gorski is an outspoken skeptic and critic of alternative medicine and the anti-vaccination movement. A prolific blogger, he writes as Orac at Respectful Insolence, and as himself at Science-Based Medicine where he is the managing editor.

<span class="mw-page-title-main">Henry Harrington Janeway</span>

Henry Harrington Janeway was an American physician and pioneer of radiation therapy.

Dr. Kodaganur S. Gopinath, MS, FAMS, FRCS (Edin) is an Indian surgical oncologist, known for his pioneering work on oncological research. He is a recipient of many awards including Dr. B. C. Roy Award, considered to be the premier medical honour in the country. The President of India recognised his services to the field of oncology, by awarding him the fourth highest civilian award, Padma Shri, in 2010.

June K. Robinson is an American dermatologist, academic and researcher. She is a Research Professor of Dermatology at Northwestern University’s Feinberg School of Medicine.

<span class="mw-page-title-main">Lynn D. Wilson</span> American radiation oncologist

Lynn D. Wilson is an American radiation oncologist. He is a professor of Therapeutic Radiology and of Dermatology, Executive Vice Chairman, Therapeutic Radiology, and Deputy Chief Medical Officer for Radiation Oncology Services at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut. In 2011, Wilson was named a Fellow of the American Society for Radiation Oncology (FASTRO).

References

  1. ↑ "Archived copy" (PDF). Archived from the original (PDF) on 2010-12-02. Retrieved 2011-10-26.{{cite web}}: CS1 maint: archived copy as title (link)
  2. ↑ "David J. Leffell, M.D., Dermatology: Yale School of Medicine". Archived from the original on 2009-01-30. Retrieved 2009-04-05.
  3. ↑ "Home , Dermatologic Surgery: Yale School of Medicine". Dermatology.yale.edu. Retrieved 2010-10-07.
  4. ↑ "Optical method and apparatus for detecting and measuring aging, photoaging, dermal disease and pigmentation in skin".
  5. ↑ "Working Knowledge". Sciamdigital.com. Retrieved 2010-10-07.
  6. ↑ Gailani, Mae R.; Ståhle-Bäckdahl, Mona; Leffell, David J.; Glyn, Michael; Zaphiropoulos, Peter G.; Undén, Anne Birgitte; Dean, Michael; Brash, Douglas E.; Bale, Allen E.; Toftgård, Rune; Toftgård, R. (1996-09-01). "The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas". Nature Genetics. 14 (1): 78–81. doi:10.1038/ng0996-78. PMID   8782823. S2CID   5221628.
  7. ↑ "Basal cell carcinoma tumor suppressor gene".
  8. ↑ "Basal cell carcinoma tumor suppressor protein".
  9. ↑ "Erivedge® (Vismodegib) | Advanced Basal Cell Carcinoma (ABCC) Treatment".
  10. ↑ McGovern, Thomas W.; Leffell, David J. (2001-12-20). "Surgical therapies, part II: flip-top transplants in vitiligo". Dermatologic Therapy. 14: 15–19. doi: 10.1046/j.1529-8019.2001.014001015.x . S2CID   73408130.
  11. ↑ Ferrucci, L. M., Cartmel, B., Molinaro, A. M., Leffell, D. J., Bale, A. E., and Mayne, S. T. Indoor tanning and risk of early-onset basal cell carcinoma. J. Am. Acad. Dermatol. 8 December 2011, doi: 10.1016/j.jaad.2011.11.940. NIHMS339428.
  12. ↑ "Making practice perfect: Medicine@Yale, May / June 2008". Archived from the original on 2011-08-26. Retrieved 2010-10-07.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.